View More
Dr Milosz Parczewski, discusses the latest data on LA PrEP, HCV treatment in PWH, and treatments for MDR TB presented at CROI 2022 and their relevance to the CEE, from Clinical Care Options (CCO).
Expert insight on key ART considerations for people with HIV requiring treatment for drug-susceptible tuberculosis (TB), from Clinical Care Options (CCO)
Slides from Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.